The European Medicines Agency (EMA) is taking proactive steps to safeguard the health of expectant mothers and their unborn children by recommending new measures to avoid exposure to the medication topiramate during pregnancy.
Topiramate is a drug commonly prescribed to treat epilepsy, migraines, and other medical conditions. However, it has been associated with an increased risk of birth defects when used during pregnancy. To address this concern, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) has conducted a thorough review of available data and proposed essential measures.
The PRAC recommends that healthcare professionals inform women of childbearing age about the potential risks associated with topiramate and consider alternative treatments for conditions, such as epilepsy or migraines, before prescribing this medication. Additionally, they suggest that women using topiramate should use effective contraception to avoid unintended pregnancies.
This proactive approach reflects the EMA's commitment to patient safety. By raising awareness and promoting responsible prescribing practices, the EMA aims to reduce the risk of birth defects associated with topiramate exposure during pregnancy. The agency continues to monitor the safety of medications, ensuring that healthcare decisions are well-informed and prioritize the well-being of both patients and their offspring.
Read more here: